Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-10-14
2010-12-14
Saeed, Kamal A (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S256000, C514S343000, C514S429000, C544S322000, C546S268100, C546S276400, C548S577000
Reexamination Certificate
active
07851463
ABSTRACT:
The invention relates to compounds of the formula (I). The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.
REFERENCES:
patent: 5708018 (1998-01-01), Haadsma-Svensson et al.
patent: 6423717 (2002-07-01), Bromidge et al.
patent: WO 95/04713 (1995-02-01), None
patent: WO 96/23760 (1996-08-01), None
patent: WO 97/45503 (1997-12-01), None
patent: WO 98/27081 (1998-06-01), None
patent: WO 99/58499 (1999-11-01), None
patent: WO 00/05225 (2000-02-01), None
J.C. Schwartz et al., The Dopamine D3Receptor as a Target for Antipsychotics, in Novel Antipsychotic Drugs, H.Y. Meltzer, Ed. Raven Press, New York, 1992, pp. 135-144.
M. Dooley et al., Drugs and Aging 1998, 12, 495-514.
J. N. Joyce, Pharmacology and Therapeutics 2001, 90, pp. 231-259 “The Dopamine D3Receptor as a Therapeutic Target for Antipsychotic and Antiparkinsonian Drugs”.
P. Sokoloff et al., Localization and Function of the D3Dopamine Receptor, Arzneim. Frosch./Drug Res. 42(1), 224 (1992).
P. Sokoloff et al., Molecular Cloning and Characterization of a Novel Dopamine Receptor (D3) as a Target for Neuroleptics, Nature, 347, 146 (1990).
Joyce, J.N. Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs. Pharmacology and Therapeutics, 2001;90:231-59.
Laszy, J., et al. Dopamine D3 receptor antagonists improve the learning performance in memory-impaired rats. Pscyhopharmacology, 2005;179:567-75.
Heidbreder, C.A., et al. The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence. Brain Research Reviews, 2005;49:77-105.
Rogoz, Z., et al. Anxiolytic-like effects of preferential dopamine D3 receptor agonists in an animal model. Polish Journal of Pharmacology, 2003;55:449-54.
Muhlbauer B., et al.. Dopamine D3 receptors in the rat kidney: role in physiology and pathophysiology. Acta Physiologica Scandinavica, 2000;168(1):219-23.
Benoit S.C., et al. Altered feeding responses in mice with targeted disruption of the dopamine-3 receptor gene. Behavioral Neuroscience, 2003;117(1):46-54.
Backfisch Gisela
Beyerbach Armin
Braje Wilfried
Drescher Karla
Grandel Roland
Abbott & GmbH & Co. KG
Bianchi Kristin
Mueller Lisa V.
Polsinelli Shughart PC
Saeed Kamal A
LandOfFree
Heterocyclic compounds suitable for treating disorders that... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterocyclic compounds suitable for treating disorders that..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic compounds suitable for treating disorders that... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4173461